GSK2334470 is a novel PDK1 inhibitor (IC50: ~10 nM, in a cell-free assay), with no inhibitory at other close related AGC-kinases.

PDK1:10 nM

The efficacy of the PDK1 inhibitor (PDKi) GSK2334470 was assessed in newborn BrafV600E::Pten?/? mice through systemic administration of 4-HT. Administering PDK1 twice weekly significantly inhibited pigmented lesions and concurrent melanomagenesis, alongside a notable reduction (~80%) in lung metastases and lymph node metastases, as quantified by H&E staining and S100 immunostaining, respectively. This outcome mirrors the effects observed with the genetic deletion of Pdk1[4].

FGFR1-4 Biochemical Assays: FGFR kinase inhibition assays are performed at KM for ATP. Picomolar to low nanomolar concentrations of FGFR proteins are incubated in 1× Kinase Reaction Buffer (KRB) with 1 μM of CSKtide and 50 to 250 of μM ATP at 25°C for 90 minutes in the presence or absence of a dosed concentration series of inhibitor. All reactions are terminated by the addition of Stop buffer, and plates are read on a Caliper EZReader2. IC50 values are fit with a four-parameter log[Inhibitor] versus response model with floating Hill Slope.

GSK2334470 is dissolved in DMSO and diluted with appropriate medium before use. To study the inhibitory effect of GSK2334470 on mTOR-S6K pathway, non-resistant cells and the resistant sublines are treated with GSK2334470 at 5 μM for 1.5 and 12 h in 10 % FBS medium with/without MK-2206 (5 μM)[2].